UCB’s Cimzia Shows Strong Interim Results In Phase IIIb For Crohn’s Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
New data bolsters firm’s appeal of a negative opinion from EU authorities.
You may also be interested in...
UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis
The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.
UCB’s Vimpat NDA Seeks Indications For Epileptic Seizures, Diabetic Pain
Belgian firm has an anticipated July 2008 user fee date for lacosamide, which was submitted as a single NDA with two indications, for partial onset seizures in epilepsy and diabetic neuropathic pain.
UCB’s Cimzia Rejected For Crohn’s By EMEA Committee
Group also refused to recommend Biogen/Elan’s Tysabri for the disease on appeal.